Neutral rating reaffirmed for Marinus stock as acquisition deal closure nears

Tuesday, Baird analyst updated the price target for Marinus (NASDAQ:MRNS) Pharmaceuticals (NASDAQ:MRNS) to $0.55, up from the previous $0.55, while maintaining a Neutral rating on the stock. The adjustment follows the announcement of an acquisition agreement with Immedica Pharma, which proposed a tender offer at a share price of $0.55. The offer comes as MRNS shares have seen a dramatic decline of over 95% from their 52-week high of $11.26. InvestingPro data shows the stock has recently surged 104% in the past week, reflecting market optimism about the deal.

Baird remarked that the acquisition did not alter the firm's outlook for Marinus Pharmaceuticals. His confidence in the successful closure of the deal prompted the price target increase. This move comes after Marinus experienced setbacks earlier in the year with the RAISE and TrustTSC clinical trials, leading the company's management to explore strategic alternatives.

According to InvestingPro analysis, the company maintains a Fair financial health score despite operating with significant debt and rapidly burning through cash. For deeper insights into MRNS's financial position and 10+ additional ProTips, subscribers can access the comprehensive Pro Research Report.

The analyst's commentary highlighted that the acquisition by Immedica Pharma had been largely anticipated following the clinical trial failures and Marinus's subsequent strategic shift. The tender offer is expected to be finalized in the first quarter of 2025.

The acquisition is set to proceed via a tender offer, a common method for acquiring a company, where shareholders are directly offered a specific price per share, in this case, $0.55. This price is now reflected in Baird's updated target for Marinus stock.

In other recent news, Immedica Pharma AB has agreed to acquire Marinus Pharmaceuticals in a deal valued at approximately $151 million. The acquisition will provide Immedica with global rights to ZTALMY® (ganaxolone) oral suspension, a medication approved for the treatment of seizures. This move is expected to enhance Immedica's growth in the North American market and contribute to its revenue growth.

Marinus Pharmaceuticals has also terminated its collaboration and supply agreements with Orion Corporation. This strategic decision will relieve Orion from a pending €500,000 development cost payment, while Marinus may potentially pay Orion €1,500,000 under certain conditions.

Furthermore, Marinus Pharmaceuticals has initiated a retention plan for its executives. This plan aims to incentivize key figures to remain during a period of strategic exploration. The company is also facing a risk of delisting from the Nasdaq due to failure to meet minimum bid price and market value requirements.

Marinus Pharmaceuticals has also seen significant changes in its board structure with three members resigning. Despite these challenges, Marinus reported Q2 net product revenues of $8 million, primarily due to ZTALMY, and plans to launch ZTALMY for tuberous sclerosis complex in 2025, targeting net product revenues between $33 million and $35 million for 2024.

Finally, Marinus has secured a new U.S. patent for ZTALMY, set to expire in September 2042. Analysts at TD Cowen and Oppenheimer have maintained a Buy rating and upgraded the stock to Outperform, respectively.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.